Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioCardia ( (BCDA) ) has provided an announcement.
On March 17, 2026, BioCardia announced that the U.S. Food and Drug Administration accepted its pre-submission package seeking marketing approval for the Helix Transendocardial Delivery Catheter, a minimally invasive system for intramyocardial delivery of therapeutic and diagnostic agents. The company has already held preliminary meetings with both the FDA’s Center for Devices and Radiological Health and Center for Biologics Evaluation and Research, with CDRH set to lead the review and a substantive review meeting scheduled for early in the second quarter.
Management indicated that potential FDA clearance of Helix would be significant for BioCardia’s business and for the broader cardiac cell, gene and protein therapy field, which lacks an FDA-approved percutaneous intramyocardial delivery platform. The Helix catheter, which uses a small distal helical needle to stabilize within the beating heart and deliver agents with improved retention to otherwise hard-to-reach regions, is also expected to support and potentially streamline regulatory progress for the company’s CardiAMP Cell Therapy for ischemic heart failure, underscoring Helix’s strategic role in BioCardia’s product portfolio and clinical pipeline.
The most recent analyst rating on (BCDA) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
Spark’s Take on BCDA Stock
According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.
The score is primarily constrained by very weak financial performance (no meaningful revenue, ongoing losses, and sustained cash burn), which elevates funding risk. Technicals also remain bearish with the stock below major moving averages, despite oversold signals. Positive clinical/regulatory updates and stated runway into 2026 provide some support, but do not outweigh the current financial and trend headwinds.
To see Spark’s full report on BCDA stock, click here.
More about BioCardia
BioCardia, Inc., headquartered in Sunnyvale, California, is a developer of cellular and cell-derived therapeutics targeting cardiovascular and pulmonary diseases. Its key platforms include the CardiAMP autologous and CardiALLO allogeneic cell therapies for heart disease, and it also serves as a biotherapeutic delivery partner for treatments in heart failure, chronic myocardial ischemia and acute myocardial infarction.
The company operates at the intersection of interventional cardiology and regenerative medicine, focusing on minimally invasive delivery technologies that enhance targeted therapeutic delivery to the heart. This positioning places BioCardia within a specialized niche of cardiac cell, gene and protein therapeutics, where effective intramyocardial delivery systems are critical to clinical and commercial success.
Average Trading Volume: 79,924
Technical Sentiment Signal: Sell
Current Market Cap: $13.48M
Learn more about BCDA stock on TipRanks’ Stock Analysis page.